ATE284675T1 - Verfahren zur vorbeugung und behandlung bakterieller infektionen unter verwendung von celluloseacetatphthalat- oder hydroxyproppylmethylcelluloseträgerstoffen - Google Patents

Verfahren zur vorbeugung und behandlung bakterieller infektionen unter verwendung von celluloseacetatphthalat- oder hydroxyproppylmethylcelluloseträgerstoffen

Info

Publication number
ATE284675T1
ATE284675T1 AT98956122T AT98956122T ATE284675T1 AT E284675 T1 ATE284675 T1 AT E284675T1 AT 98956122 T AT98956122 T AT 98956122T AT 98956122 T AT98956122 T AT 98956122T AT E284675 T1 ATE284675 T1 AT E284675T1
Authority
AT
Austria
Prior art keywords
preventing
cellulose acetate
hpmcp
cap
hydroxyproppylmethylcellulose
Prior art date
Application number
AT98956122T
Other languages
English (en)
Inventor
Alexander Robert Neurath
Shibo Jiang
Asim Kumar Debnath
Nathan Strick
Gordon Jay Dow
Original Assignee
New York Blood Ct Inc
Alexander Robert Neurath
Shibo Jiang
Asim Kumar Debnath
Nathan Strick
Dow Gordon J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/112,130 external-priority patent/US5985313A/en
Application filed by New York Blood Ct Inc, Alexander Robert Neurath, Shibo Jiang, Asim Kumar Debnath, Nathan Strick, Dow Gordon J filed Critical New York Blood Ct Inc
Application granted granted Critical
Publication of ATE284675T1 publication Critical patent/ATE284675T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT98956122T 1997-10-22 1998-10-21 Verfahren zur vorbeugung und behandlung bakterieller infektionen unter verwendung von celluloseacetatphthalat- oder hydroxyproppylmethylcelluloseträgerstoffen ATE284675T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6293697P 1997-10-22 1997-10-22
US7101798P 1998-01-13 1998-01-13
US09/112,130 US5985313A (en) 1997-10-22 1998-07-08 Method for decreasing the frequency of transmission of viral infections using cellulose acetate phthalate or hydroxypropyl methylcellulose phthalate excipients
US09/175,909 US6165493A (en) 1997-10-22 1998-10-20 "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"
PCT/US1998/022184 WO1999020098A1 (en) 1997-10-22 1998-10-21 Methods for preventing and treating bacterial infections using cellulose acetate phthalate or hydroxypropyl methylcellulose phthalate excipients

Publications (1)

Publication Number Publication Date
ATE284675T1 true ATE284675T1 (de) 2005-01-15

Family

ID=27490333

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98956122T ATE284675T1 (de) 1997-10-22 1998-10-21 Verfahren zur vorbeugung und behandlung bakterieller infektionen unter verwendung von celluloseacetatphthalat- oder hydroxyproppylmethylcelluloseträgerstoffen

Country Status (9)

Country Link
US (1) US6165493A (de)
EP (1) EP1030547B1 (de)
JP (1) JP2001520171A (de)
AT (1) ATE284675T1 (de)
AU (1) AU1271799A (de)
BR (1) BR9813137A (de)
CA (1) CA2305331C (de)
DE (1) DE69828196T2 (de)
WO (1) WO1999020098A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US6462030B1 (en) * 1999-07-19 2002-10-08 New York Blood Center, Inc. Method for inactivating bacteria associated with bacterial vaginosis using cellulose acetate phthalate and/or hydroxypropyl methycellulose phthalate
US6541517B1 (en) * 1999-09-03 2003-04-01 Donald M. Murphy Treatment of skin disorders
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
US6835717B2 (en) * 2000-03-08 2004-12-28 The Johns Hopkins University School Of Medicine β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
US6541542B2 (en) 2000-09-29 2003-04-01 Eastman Chemical Company Process for production of polymeric powders
US6572875B2 (en) 2000-10-30 2003-06-03 New York Blood Center, Inc. Biodegradable microbicidal vaginal barrier device
US6596297B2 (en) 2000-10-30 2003-07-22 New York Blood Center, Inc. Biodegradable microbicidal vaginal barrier device
JP2002154906A (ja) * 2000-11-13 2002-05-28 Michio Hayashi 抗菌剤組成物
US20030133829A1 (en) * 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
US7008979B2 (en) 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
GB2398496A (en) * 2003-02-20 2004-08-25 Reckitt Benckiser Healthcare Suspensions of water-swellable polymer particles which are substantially water-free or contain insufficient water to fully swell the particles
US20050070501A1 (en) * 2003-09-29 2005-03-31 New York Blood Center, Inc. Water dispersible film
JP5122821B2 (ja) 2003-11-28 2013-01-16 イーストマン ケミカル カンパニー セルロースインターポリマー及び酸化方法
US20060021302A1 (en) * 2004-07-30 2006-02-02 Bernard Bobby L Anti-microbial air filter
US20070082035A1 (en) 2005-10-06 2007-04-12 New York Blood Center, Inc. Anti-infective hygiene products based on cellulose acetate phthalate
US7772213B2 (en) * 2006-07-27 2010-08-10 Nathan Strick Composition for the treatment of inflammatory conditions
AU2008211199A1 (en) * 2007-01-26 2008-08-07 The Regents Of The University Of Colorado Methods of modulating immune function
AU2008256689A1 (en) * 2007-05-24 2008-12-04 New York Blood Center Inc. Rapidly dispersible vaginal tablet that provides a bioadhesive gel
EP2215108A4 (de) 2007-10-23 2012-07-04 Univ Colorado Kompetitive inhibitoren der expression der konstanten kette und/oder der ektopischen klipp-bindung
US20090234027A1 (en) * 2008-03-14 2009-09-17 Nathan Strick Topical gel cosmetic formulation of cellacefate for the control of acne and rosacea
CA2658440C (en) 2008-04-04 2016-08-23 Kraft Foods Global Brands Llc Dairy composition with probiotics and anti-microbial system
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
AU2009274568A1 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Proteins for use in diagnosing and treating infection and disease
WO2010011343A2 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Methods for treating viral disorders
US20110189221A1 (en) * 2008-10-31 2011-08-04 Van Olphen Alberto Novel antiviral compounds from marine extracts
WO2012019991A1 (en) 2010-08-09 2012-02-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of hiv-1 infections
EP3049106A1 (de) 2013-09-25 2016-08-03 Zoetis Services LLC Divergente impfstoffzusammensetzung gegen pcv2b und verfahren zur verwendung
EP3468530A4 (de) 2016-06-10 2020-03-11 Clarity Cosmetics Inc. Nichtkomedogene formuliereungen zur haar- und kopfhautpflege und verfahren zur verwendung

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
US4330338A (en) * 1978-10-02 1982-05-18 Purdue Research Foundation Pharmaceutical coating composition, and preparation and dosages so coated
US4518433A (en) * 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4462839A (en) * 1983-06-16 1984-07-31 Fmc Corporation Enteric coating for pharmaceutical dosage forms
WO1988008011A1 (en) * 1987-04-16 1988-10-20 Christian Bindschaedler Process for preparing a powder of water-insoluble polymer which can be redispersed in a liquid phase, the resulting powder and utilization therof
US4960814A (en) * 1988-06-13 1990-10-02 Eastman Kodak Company Water-dispersible polymeric compositions
US5025004A (en) * 1988-06-13 1991-06-18 Eastman Kodak Company Water-dispersible polymeric compositions
US5326572A (en) * 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
US5356634A (en) * 1992-11-13 1994-10-18 Eastman Chemical Company Controlled-release delivery system
US5380790A (en) * 1993-09-09 1995-01-10 Eastman Chemical Company Process for the preparation of acrylic polymers for pharmaceutical coatings
JP3492787B2 (ja) * 1994-04-15 2004-02-03 信越化学工業株式会社 固形製剤のコーティング用水性エマルジョンの濃縮方法
EP0706794B1 (de) * 1994-10-14 2001-12-12 Japan Energy Corporation AIDS-hemmende Arzneizubereitung und Verfahren
US5723151A (en) * 1995-11-06 1998-03-03 Eastman Chemical Company Cellulose acetate phthalate enteric coating compositions
US5646151A (en) * 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof

Also Published As

Publication number Publication date
CA2305331A1 (en) 1999-04-29
WO1999020098A1 (en) 1999-04-29
DE69828196D1 (de) 2005-01-20
EP1030547A4 (de) 2002-11-06
AU1271799A (en) 1999-05-10
BR9813137A (pt) 2000-08-15
EP1030547A1 (de) 2000-08-30
JP2001520171A (ja) 2001-10-30
DE69828196T2 (de) 2006-02-23
US6165493A (en) 2000-12-26
EP1030547B1 (de) 2004-12-15
CA2305331C (en) 2008-04-29

Similar Documents

Publication Publication Date Title
ATE284675T1 (de) Verfahren zur vorbeugung und behandlung bakterieller infektionen unter verwendung von celluloseacetatphthalat- oder hydroxyproppylmethylcelluloseträgerstoffen
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
DE69535018D1 (de) Papillomavirus vakzine
FR2742756B1 (fr) Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
ATE275406T1 (de) Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden
FI951468A0 (fi) Lipopeptidijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
DE60110106D1 (de) Verfahren zur herstellung von pankreasenzym enthaltende mikrosphären mit hoher stabilität
DK0760649T3 (da) Præparater af fluticason-propionat
DE69627024D1 (de) Prophylaktische immunisierende milchpräparation gegen otitis
MY164523A (en) Methods and compositions for treating hepatitis c virus
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
WO1999029717A3 (en) Postweaning multisystemic wasting syndrome virus from pigs
CA2258217A1 (en) Substituted cyclopentane compounds useful as neuraminidase inhibitors
DE69128898D1 (de) Selbstständig zusammenfügende replikationsdefekte hybride viruspartikel
UA85543C2 (ru) Способ культивирования первичных клеток и амплификации вирусов в условиях безсывороточной среды, композиция и ее применение, и способ лечения или вакцинации животных
ATE516034T1 (de) Verfahren zur modulation der immunreaktion in einem infektierten säugetier mittels transmukosales eingeben eines modulationsmittel
EP0734387A4 (de) Hiv-proteaseinhibitoren
AU3855297A (en) Pharmaceutical composition for treating papillomavirus tumours and infection
WO1997005899A3 (en) Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
ATE380034T1 (de) Neues verfahren zur herstellung von virus- ähnlichen partikeln des menschen-papillomavirus mit verbesserten eigenschaften
DE68923169D1 (de) Verwendung von fluor enthaltenden Pyridoncarbonsäure-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von HIV infektionen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties